Daily Endocrinology Research Analysis
Analyzed 84 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology-related studies stood out today: a multi-modal, externally validated model that enables early prediction of gestational diabetes using routine NIPT cell-free DNA plus genetics and clinical data; a nationwide prospective registry defining real-world presentation and prognostic thresholds (Ki-67 ≥15%) in gastroenteropancreatic neuroendocrine neoplasms; and a large comparative effectiveness analysis suggesting clomiphene may have fewer adverse outcomes and lower mortality than testosterone therapy for male hypogonadism.
Research Themes
- Early genomic/cfDNA-enabled risk prediction in endocrine-metabolic pregnancy complications
- Real-world neuroendocrine tumor prognostication and biomarker thresholds
- Comparative effectiveness and safety of therapies for male hypogonadism
Selected Articles
1. Early prediction of gestational diabetes mellitus with clinical characteristics, cell-free DNA and genetic variants.
Using routinely collected NIPT cfDNA signals (TSS coverage), a polygenic risk score, and clinical features, the authors achieved up to AUC 0.89 for early GDM prediction; a clinical+cfDNA model generalized well (AUC 0.83) in external validation. PRS alone reached AUC 0.75, and integrating modalities improved sensitivity and specificity.
Impact: Demonstrates a practical, scalable pathway to early GDM risk stratification by repurposing NIPT cfDNA plus genetics with external validation, potentially enabling earlier interventions.
Clinical Implications: Health systems could integrate cfDNA-derived features with clinical data to triage women early in pregnancy for preventive counseling, lifestyle or pharmacologic trials, and intensified monitoring.
Key Findings
- Polygenic risk score alone discriminated GDM with AUC 0.75.
- cfDNA TSS coverage identified 357 differential genes; a 166-gene cfDNA signature achieved AUC 0.83 and 0.85 when combined with clinical features.
- Integrating clinical features, cfDNA, and SNVs via random forest yielded AUC 0.89 (sensitivity 0.89, specificity 0.74).
- External validation across two centers showed a clinical+cfDNA linear model with AUC 0.83.
Methodological Strengths
- External validation in independent cohorts (n=2,350).
- Use of routinely collected NIPT cfDNA signals and comparison of multiple machine-learning approaches.
Limitations
- Primarily retrospective data assembly; potential selection bias and limited ancestry diversity not detailed.
- Clinical utility thresholds, workflow integration, and cost-effectiveness were not tested prospectively.
Future Directions: Prospective implementation trials across ancestries to assess calibration, impact on maternal-fetal outcomes, equity, and cost-effectiveness; harmonization of cfDNA pipelines and model governance.
BACKGROUND: Gestational diabetes mellitus (GDM) remains a prevalent and heterogeneous pregnancy complication with limited strategies for early identification. We aimed to investigate efficient approaches for early prediction of GDM with clinical and genetic risk factors. METHODS: A previously developed machine-learning model based on clinical characteristics achieved an area under the curve (AUC) of 0.77. To improve predictive accuracy, we further collected non-invasive prenatal testing (NIPT) results from 595 pregnant women (295 with
2. Real-world presentation and outcomes of gastroenteropancreatic neuroendocrine neoplasms in Italy: findings from the nationwide Itanet prospective database.
In a nationwide prospective registry of 2,138 Italian patients with newly diagnosed GEP-NENs, most tumors were well-differentiated, frequently pancreatic or ileal, and over half were incidental. Ki-67 behaved as a continuous prognostic biomarker, with a 15% threshold associated with worse survival, offering a practical benchmark for risk stratification.
Impact: Provides high-quality, contemporary, real-world benchmarks for diagnosis-to-treatment pathways and validates a pragmatic Ki-67 threshold for prognosis in GEP-NENs.
Clinical Implications: Supports risk-adapted care pathways; Ki-67 assessed as a continuous variable with a 15% threshold can inform surveillance intensity and systemic therapy decisions.
Key Findings
- 2,138 consecutive GEP-NENs across 38 centers; 90.8% were well-differentiated NETs.
- Primary sites: pancreas 41.4% and ileum 19.7%; incidental diagnosis occurred in 58.6% of cases.
- Among symptomatic patients, mean diagnostic delay was 197 days (longer for pancreatic than small bowel).
- Ki-67 modeled continuously predicted outcome; a 15% threshold identified significantly worse survival.
Methodological Strengths
- Nationwide, prospective, multicenter cohort with central data validation.
- Large sample size enabling robust survival and subgroup analyses; Ki-67 modeled as a continuous variable.
Limitations
- Observational design; potential residual confounding and center-level practice variation.
- Maturity of long-term outcomes is limited by contemporary enrollment period (2019–2024).
Future Directions: Incorporate molecular profiling with Ki-67 to refine risk models; evaluate how the 15% threshold guides therapy selection and outcomes in pragmatic trials.
BACKGROUND: The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) is increasing, but population registries seldom capture detailed clinical data. The Italian Association for Neuroendocrine Tumours (Itanet) established a nationwide prospective database to describe presentation, diagnostic pathways, management, and outcomes of newly diagnosed GEP-NENs in Italy. METHODS: This multicentre prospective observational study enrolled 2138 consecutive patients with newly diagnosed GEP-NENs across 38 Italian centres (2019-2024). Clini
3. Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans.
In a propensity score–matched VA cohort (2,518 per group), clomiphene was associated with lower incidences of hypertension, stroke, coronary artery disease, polycythemia, osteoporosis, and markedly lower all-cause mortality than testosterone therapy. Clomiphene increased testosterone in a physiological manner.
Impact: Challenges routine reliance on testosterone therapy by suggesting a safer alternative with favorable outcomes in a large real-world cohort, informing shared decision-making.
Clinical Implications: For men desiring fertility preservation or with cardiometabolic risk, clomiphene may be a preferred first-line option; careful patient selection and monitoring remain essential given observational design.
Key Findings
- Propensity score–matched analysis compared 2,518 clomiphene vs 2,518 testosterone-treated veterans.
- Lower incidences with clomiphene: hypertension (6.04% vs 10.48%), cerebrovascular accident (0.52% vs 1.43%), coronary artery disease (1.51% vs 2.26%), polycythemia (1.07% vs 2.22%), osteoporosis (1.15% vs 2.07%).
- All-cause mortality was lower with clomiphene (1.83%) vs testosterone therapy (10.13%).
- Clomiphene increased testosterone levels relative to baseline in a physiological pattern.
Methodological Strengths
- Large national dataset with 1:1 propensity score matching to balance baseline characteristics.
- Assessment of multiple clinically relevant adverse outcomes and mortality.
Limitations
- Retrospective observational design susceptible to residual confounding and confounding by indication.
- Generalizability may be limited to veteran population; detailed follow-up duration not provided.
Future Directions: Prospective randomized trials comparing clomiphene vs testosterone on cardiovascular, hematologic, skeletal outcomes and fertility, with patient-centered endpoints.
BACKGROUND: Male hypogonadotropic hypogonadism is a complex condition with a multifactorial etiology. Although testosterone replacement therapy (TRT) is the only approved treatment for male hypogonadism, clomiphene citrate (CC) is often used as an off-label treatment. OBJECTIVES: The present study was conducted to objectively compare clinical outcomes, including adverse effects in patients receiving clomiphene citrate and testosterone replacement therapy. MATERIALS AND METHODS: This is a retrospective study of data collected through the